How Will the UK MHRA Proposed Medical Device Regulation Amendments Affect Chinese Companies?

The proposed amendments to the UK MHRA medical device regulations are expected to affect Chinese companies by reinforcing patient safety, UDI, implant card, IVD classification and technical documentation responsibilities, while exploring a faster route that can make use of approvals from mature regulators such as Australia, Canada and the United States. Chinese companies entering the UK market should not focus only on the UKCA certificate itself; they should also prepare, in advance, existing approvals from mature markets, review dossiers, post-market data, labels and instructions for use, UDI information and UK Responsible Person responsibilities.

Published: 2026-07-08 09:00 Updated: 2026-07-08 09:00

This FAQ addresses priorities that companies need to assess in practical international medical device registration, documentation preparation, compliance pathways and post-market maintenance projects.

Key summary

The proposed amendments to the UK MHRA medical device regulations reflect the future direction of UK regulation: strengthening patient safety, UDI, implant cards, IVD classification and technical documentation responsibility, while exploring faster use of approvals from mature regulators such as Australia, Canada and the United States. When Chinese companies enter the UK market, they should not focus only on the UKCA certificate itself; they should also prepare existing mature-market certificates, review dossiers, post-market data, labels and instructions for use, UDI information and UK Responsible Person arrangements in advance.

Reference basis

Official source: MHRA

Source link: https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation

This article is compiled from publicly available official information and AIMEILI international registration project experience. The specific pathway should still be determined according to product risk class, intended purpose and the latest requirements of the regulatory authority.

Who should read this

This content is suitable for medical device manufacturers, regulatory affairs staff, overseas market managers and CRO teams preparing UKCA and international recognition related projects. If a company already has China, EU, US or other market documentation but is not sure whether it can be reused in the target market, it should also read this and complete a gap assessment before project initiation.

Regulatory assessment logic

Companies should first confirm the product regulatory status, risk class, intended purpose, applicable regulatory pathway and local responsible entity, and then determine the required depth of documentation. MHRA-related requirements usually do not look at a single document alone; they also assess whether product claims, technical evidence, labels and instructions for use, quality system and post-market responsibilities are consistent.

Documentation priorities

It is advisable to build a documentation package around product description, model specifications, risk management, performance verification, clinical or evaluation evidence, quality system, labels and instructions for use, authorisation documents, UDI or traceability information, change management and post-market surveillance. For software, AI, IVD, sterile, active and medium-to-high risk products, additional specialised evidence should also be provided.

Practical steps for companies

• Establish a product and model list.
• Reclassify products according to the target market.
• Check the coverage of existing certificates and test reports.
• Identify labelling, language, local representative and post-market obligations.
• Create a gap list and supplementary documentation plan.
• Then arrange translation, signing, submission and responses to review questions.

Common errors

Common errors include directly translating domestic documentation, ignoring the local responsible entity, over-relying on existing CE or FDA documentation, unclear product model coverage, label claims that exceed the evidence scope, and missing post-market surveillance and change processes. What regulators truly focus on is whether the evidence chain is closed, not the number of documents.

AIMEILI professional recommendations

AIMEILI recommends incorporating this issue into the registration project initiation assessment rather than supplementing documents only before submission. A more robust approach is to complete pathway determination and documentation gap assessment first, and then manage the target country, product classification, documentation reuse, supplementary testing, local representative and post-market maintenance in the same project plan.

Internal checklist

• Are product classification, intended purpose and model scope clearly defined?
• Do existing certificates, test reports and technical documentation cover the intended submission scope?
• Are the responsibilities of the local representative, Sponsor or registration holder clearly defined?
• Have labels and instructions for use, UDI, language and post-market maintenance been planned?
• Has a documentation gap list and supplementary testing plan been created?
• Are official sources and applicability boundaries documented?

Continue reading

Previous: How do the Korean MFDS clinical trial guidelines for machine learning medical devices affect companies?

Next: Why is it important to focus on technical documentation and the local responsible entity for Saudi SFDA MDMA registration?

Recommended reading:

• What should companies prepare before Australian TGA medical device registration?
• Can CE documentation be reused for Singapore HSA medical device registration?
• What core documentation is required for UAE MOHAP medical device registration?
• Why is the Brazilian ANVISA medical device registration cycle so long?
• What is the difference between a Vietnamese medical device import licence and registration certificate?
• How should an Indonesian medical device registration local agent be selected?

Return to FAQ Centre

News and insights

Contact AIMEILI

Content review and applicability boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions or legal opinions.